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Abstract: The accurate assessment of lymph node involvement is an
important part of the management of lung cancer. Lymph node “maps”
have been used to describe the location of nodal metastases. However,
discrepancies in nomenclature among maps used by Asian and Western
countries hinder analyses of lung cancer treatment outcome. To achieve
uniformity and to promote future analyses of a planned prospective
international database, the International Association for the Study of
Lung Cancer proposes a new lymph node map which reconciles
differences among currently used maps, and provides precise anatomic
definitions for all lymph node stations. A method of grouping lymph
node stations together into “zones” is also proposed for the purposes of
future survival analyses.
KeyWords: Lung cancer lymph node map, Lung cancer staging, Pulmo-
nary and mediastinal lymph nodes, lymph node zones, TNM classification.
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The accurate assessment of lymph node involvement is rec-ognized as a pivotal component of the staging and treatment
of lung cancers. For approximately the past 40 years, lymph
node “maps” have been used to describe the clinical and patho-
logic extent of lymph node metastases in lung cancer patients by
labeling regions of intrathoracic nodes using a system of ana-
tomic descriptors and numerical “levels.” Precise, universally
accepted nomenclature to describe lymph node involvement is
key to assessing treatment outcomes, comparing results across
institutions, designing and analyzing clinical trials, and selecting
therapy for individual patients. The first lymph node map,
developed by Naruke1,2 during the 1960s, was initially widely
used in North America, Europe, and Japan (Figure 1). However,
subsequent attempts to refine the anatomic descriptors of the
Naruke map led to the development of maps by the American
Thoracic Society (ATS)3 and to the so-called Mountain-Dresler
modification of the ATS map (MD-ATS).4 The MD-ATS map
(Figure 2) attempted to unify in a single system the features of
the Naruke lymph node classification and the schema developed
by the ATS and was reportedly adopted by the American Joint
Committee on Cancer (AJCC) and the Prognostic Factors TNM
Committee of the International Union Against Cancer (UICC) at
the 1996 annual meetings of these organizations.4 Subsequently,
the MD-ATS map was fully accepted across North America but
was only sporadically used in Europe. Indeed, further revisions
to the MD-ATS map were suggested by European surgeons.5
Following well-established national practice patterns, Japanese
surgeons and oncologists continued to use the Naruke map as
advocated by the Japan Lung Cancer Society.6
In 1998, the International Association for the Study
of Lung Cancer (IASLC) established its Lung Cancer
Staging Project which led to the development of an inter-
national lung cancer database. Analyses of that database
enabled the IASLC International Staging Committee to
propose revisions of the TNM staging system for lung
cancer which will be included in the 7th editions of the
UICC and AJCC staging manuals to be published in 2009.7
Analyses of the N descriptors in the IASLC international
database highlighted discrepancies in nomenclature be-
tween the Japanese (Naruke) and the MD-ATS lymph node
maps. Important differences in the descriptors for medias-
tinal lymph nodes included level 1 lymph nodes in the
Naruke map corresponding to levels 1 and 2 in the MD-
ATS map, while levels 2, 3, 4R, and 4L in the Japanese
system corresponded to levels 4R and 4L in the MD-ATS
map. Perhaps the most significant discrepancy was that
level 7 subcarinal lymph nodes in the MD-ATS map
corresponded to levels 7 and 10 in the Naruke map. As a
result, some tumors staged as N2, stage IIIA according to
the MD-ATS map, were staged as N1, stage II by the
Naruke map. Within the context of a retrospective study,
this difference in nomenclature introduced an irreconcil-
able discrepancy in data analysis.8 As a consequence of the
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difficulties encountered in analyses of N descriptors, mem-
bers of the IASLC staging committee were charged to
develop a revised lymph node map that would reconcile
differences between the Japanese and MD-ATS maps and
provide more specific anatomic definitions for each of the
lymph node stations. This effort was considered critical to
the prospective international lung cancer data collection
planned by the IASLC starting in 2009 which will inform
revisions for the 8th editions of the UICC and AJCC
staging manuals 7 years hence. We now describe the
IASLC lymph node map which we anticipate will super-
sede all previous maps for the purposes of precision and
international uniformity in nomenclature.
METHODS
Two of the authors (V.R., H.A.) were assigned by the
IASLC Staging Committee to lead the effort in developing a revised
lymph node map that would reconcile the differences between the
Naruke and the MD-ATS maps and refine the definitions of the
anatomic boundaries of each of the lymph node stations.
Areas of discrepancy for the descriptors of each lymph
node station were identified and new, clarifying definitions for
FIGURE 1. The Naruke lymph node
map for the staging of lung cancers
as recommended by the Japan Lung
Cancer Society.6
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the anatomic borders established (Table 1). A collaborating
thoracic radiologist (H.W.) reviewed the definitions to insure
that they could be applied to clinical staging by computed
tomography (CT), and generated the CT scan illustrations that
corresponded to the IASLC lymph node map definitions. The
recommendations for the definitions of the lymph node stations and
for the illustration of the proposed IASLC map were reviewed by
the entire IASLC staging committee, an international multidisci-
plinary group including thoracic surgeons, medical and radiation
oncologists, pulmonologists, epidemiologists, radiologists, patholo-
gists, and data managers. In addition, one of the authors (H.A.)
presented the proposed lymph node map and anatomic definitions at
thoracic meetings in Japan for comments and approval.
RESULTS
The proposed IASLC lymph node map and the ana-
tomic definitions for each of the lymph node stations are
FIGURE 2. The Mountain-Dresler modification of the lymph node map originally proposed by the American Thoracic Society.4
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shown in Figure 3 and Table 1, respectively. There are
several notable changes relative to the Naruke and MD-ATS
maps. Concise and anatomically distinct descriptions are now
provided for all lymph node stations and especially for the
upper and lower borders of lymph node stations 1 through 10
where it is critical to avoid overlap in definitions. As a result,
the pleural reflection no longer serves as the border between
nodal stations 4 and 10, which are now defined by anatomic
landmarks that are more reliably identified on imaging studies
and at endoscopy and surgery. The supraclavicular and ster-
nal notch lymph nodes which were not previously identified
as a lymph node station separate from the intrathoracic nodes
are now clearly described as level 1. The discrepancies
between levels 2 and 4 lymph nodes in the Naruke and
MD-ATS lymph node maps (noted above) have been re-
solved by providing more precise definitions. The arbitrary
division along the midline of the trachea created by the ATS
has been eliminated. Recognizing that lymphatic drainage in
the superior mediastinum predominantly occurs to the right
paratracheal area and extends past the midline of the trachea,
the boundary between the right- and left-sided levels 2 and 4
lymph nodes has been reset to the left lateral wall of the
trachea (Figures 3, 4). The arbitrary designation of level 3
lymph nodes as nodes overlying the midline of the trachea in
the Naruke map has been eliminated because these nodes are
not reliably distinguishable from levels 2 and 4 and are
generally removed en-bloc with level 4 during a mediastinal
component of systematic nodal dissection from the right. The
designation of prevascular (anterior mediastinal) and retro-
tracheal nodes as 3a and 3p has been retained and clarified.
The entire subcarinal group of lymph nodes, previously
labeled as level 7 in the MD-ATS map but divided into levels
7 and 10 in the Naruke map is now defined as level 7, again
with precise anatomic borders. Specific boundaries are also
provided for the frequently problematic separation between
levels 4 and 10 on the right, levels 5 and 10 on the left, and
levels 10 and 11 bilaterally. Exploratory analyses of overall
survival in relationship to various levels of lymph node
involvement previously grouped together certain lymph node
stations into “zones.”8 The zone concept is proposed for
future survival analyses, not for current standard nomencla-
ture. It is hoped that this concept will prove of value to
oncologists and radiologists when dealing with large nodal
masses that transgress individual nodal stations.
Figures 4A–F illustrate how the anatomic definitions of
the lymph node stations are applied to clinical staging on CT
scans in the axial (Figures 4A–C), coronal (Figure 4D), and
sagittal (Figures 4E, F) views. The division between right and
left sided nodes at levels 2 and 4 is also shown (Figures 4A, B).
DISCUSSION
Scientific investigation into the patterns of lymphatic
drainage of the lung dates back to the early 1900s. However,
Rouvie`re9 is generally credited with the first comprehensive
study of the lymphatic drainage of the lung. In 1929, he de-
scribed the lymph nodes draining each lobe of the lung as
determined by selective injection of the lymphatics in 200
human specimens. In his report, he noted that it was possible toTA
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predict which lymph nodes would be involved based on the
location of the primary tumor. The illustrations of lobar lym-
phatic drainage included in this seminal article have been cor-
roborated by more recent studies and are still accurate today.
During the 1950s and 1960s additional studies expanded our
knowledge of the patterns of pulmonary and mediastinal lym-
FIGURE 3. The International Association for the Study of Lung Cancer (IASLC) lymph node map, including the proposed
grouping of lymph node stations into “zones” for the purposes of prognostic analyses.
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phatic drainage especially in patients with lung cancer.10,11 More
recently, Riquet defined the lymphatic drainage of lung seg-
ments including direct drainage to mediastinal lymph nodes by
injecting the subpleural lymphatics of 483 lung segments in 260
adult cadavers.12 Overall, these various studies indicated that
mediastinal lymph node metastases from right upper lobe tu-
mors occur predominantly in the right paratracheal area, while
those from left upper lobe tumors occur most frequently in the
peri- and subaortic lymph nodes, and those from middle and
lower lobe tumors occur in the subcarinal, then the right para-
tracheal nodes. Direct drainage to the mediastinal lymph nodes
bypassing the hilar and interlobar nodes or so-called skip me-
tastases, can be seen in up to 25% of lung segments injected
experimentally.12 Clinically, skip metastases have been reported
in 7 to 26% of resected lung cancer specimens and are most
frequent in upper lobe tumors and in adenocarcinomas.13,14
Studies of the patterns of lymphatic drainage of the lung
gradually led to an understanding of the importance of lymph
node staging in the management of lung cancers. Cahan is
credited with the first description of a systematic approach to
hilar and mediastinal lymph node dissection, initially in 1951 in
conjunction with pneumonectomy,15 and later, in 1960, in asso-
ciation with lobectomy.16 Shortly thereafter, Ishikawa intro-
duced the dissection proposed by Cahan to Japan and based on
the results of patients undergoing pulmonary resection with hilar
and mediastinal lymph node dissection by Ishikawa and his
FIGURE 4. A–F: Illustrations of how the International Association for the Study of Lung Cancer (IASLC) lymph node map can
be applied to clinical staging by computed tomography scan in axial (A–C), coronal (D), and sagittal (E, F) views. The border
between the right and left paratracheal region is shown in A and B. Ao, aorta; AV, azygos vein; Br, bronchus; IA, innominate
artery; IV, innominate vein; LA, ligamentum arteriosum; LIV, left innominate vein; LSA, left subclavian artery; PA, pulmonary
artery; PV, pulmonary vein; RIV, right innominate vein; SVC, superior vena cava.
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team, Naruke created his lymph node map in 1967. The Japan
Lung Cancer Society endorsed lymph node dissection and the
Naruke map as standard procedure for lung cancer resection in
1980.17,18 In North America during the 1960s, the group at
Memorial Sloan-Kettering Cancer Center (of which Cahan was
part) devised a lung cancer staging system and lymph node
nomenclature similar to the Naruke system.19 However, ulti-
mately, MSKCC and other North American groups adopted the
Naruke map which was then accepted in 1976 by the AJC
(American Joint Committee for Cancer Staging and End Results
Reporting) for standard use in the staging of lung cancers. The
need to provide more precise anatomic definitions for intratho-
racic lymph node stations in a way that would be useful for
radiologists, pathologists, and all clinicians involved in the care
of lung cancer patients led to the development of the ATS and
MD-ATS maps. The presence of these two mapping systems
was acknowledged starting in 1997 with the 4th edition of the
UICC TNM Atlas20 and the 5th and 6th editions of the AJCC
staging manuals.21 During this time, the Japan Lung Cancer
Society refined the anatomic definitions of the lymph node
stations in the Naruke map. Detailed descriptions as well as
anatomic and CT illustrations provided in the Japan Lung
Cancer Society monograph Classification of Lung Cancer es-
tablished national standards of staging and pathologic classifi-
cation for lung cancer with a degree of precision unparalleled
elsewhere in the world. Unfortunately, an English edition of this
monograph was not published until 2000.6 Therefore, although
clinicians, especially surgeons, were generally aware of discrep-
ancies between the Japanese and MD-ATS map and knew that
such differences could affect analyses of treatment outcomes
because of their impact on staging, the extent of these discrep-
ancies was not evident until recently. The difficulties in assess-
ing the outcomes of treatment for patients staged accordingly to
different lymph node maps are emphasized by the complexities
and irreconcilable discrepancies encountered during analyses of
the N descriptors in the IASLC database.8 However, discrepan-
cies in the labeling of lymph node stations occur even among
experienced Japanese and non-Japanese surgeons utilizing only
the Naruke map. In one study, a Japanese surgeon and a
European surgeon who were jointly present during pulmonary
resections performed on 41 patients designated in a manner
blinded to one another each lymph node station removed during
a systematic lymph node dissection. The total concordance rate
was only 68.5%. Of even greater concern was that in 34.1% of
patients, lymph nodes designated as N1 by one surgeon were
labeled as N2 by the other surgeon.22 Clearly, a single interna-
tionally accepted lymph node map is needed for future studies of
lung cancer treatment and revisions of the staging system. This
is especially important during the coming decades as an increas-
ing number of developing countries with large lung cancer
patient populations that have not systematically used either one
lymph node map or the other in the past begin to contribute their
data to the prospective international IASLC database.
Analyses of outcome in relationship to the extent of lymph
node involvement have been used to propose changes to the lung
cancer staging system, to select patients for multimodality treat-
ment and to stratify patients within clinical trials. The published
surgical literature is replete with such analyses, which are too
numerous to list in their entirety here.13,23–33 Areas of continuing
controversy regarding the relationship between lymph nodes
metastases and overall survival include: intranodal versus ex-
tranodal disease23; single versus multiple (either N1 or N2)
lymph node station disease13,24,27–32; the specific sites of lymph
node metastases in relationship to the location of the primary
tumor24,28,31; the significance of skip metastases13; and the need
for systematic lymph node dissection versus a less extensive
lymph node sampling,25 especially for tumors less than 2 cm in
size.26 Analyses of the IASLC database suggested that left upper
lobe tumors with skip metastases in the AP zone (levels 5 and 6)
were associated with a more favorable prognosis than other N2
subsets. In addition, analyses of the potential impact of the
number of involved lymph node zones on survival found three
groups to have significantly different survival rates: patients who
had N1 single zone disease, those who had either multiple N1 or
single N2 zone metastases, and those who had multiple N2
lymph node zones involved. However, a firm recommendation
for changes in the N descriptors and stage groupings could not
be made because larger numbers of patients with precise lymph
node staging that can be analyzed across each T stage are
required to yield statistically valid results. Grouping together
patient groups according to lymph node “zones” was a
mechanism used in the analysis of the retrospective IASLC
database to reconcile the Naruke and the MD-ATS lymph
node maps which seemed justified on the basis of explor-
atory analyses.8 Prospective analyses in larger number of
uniformly staged patients are required to determine whether
grouping lymph node stations together into “zones,” as pro-
posed here, is truly appropriate for analyses of survival. The
continuing controversies about the current N classifications
and the challenges encountered by the IASLC staging com-
mittee in analyzing an international database attest to the need
for an internationally accepted lymph node map that will
support an uniform approach to lymph node staging.34 It is
our hope that widespread implementation of the IASLC
lymph node map will provide the basis for future analyses to
resolve many of the controversies about N stage classification
that currently affect patient care and clinical trials.
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